Value added medicines: what value repurposed medicines might bring to society?

Abstract

Background & objectives: Despite the wide interest surrounding drug repurposing, no common terminology has been yet agreed for these products and their full potential value is not always recognised and rewarded, creating a disincentive for further development. The objectives of the present study were to assess from a wide perspective which value drug repurposing might bring to society, but also to identify key obstacles for adoption of these medicines and to discuss policy recommendations. Methods: A preliminary comprehensive search was conducted to assess how the concept of drug repurposing was described in the literature. Following completion of the literature review, a primary research was conducted to get perspective of various stakeholders across EU member states on drug repurposing (healthcare professionals, regulatory authorities and Health Technology Assessment (HTA) bodies/payers, patients, and representatives of the pharmaceutical industry developing medicines in this field). Ad hoc literature review was performed to illustrate, when appropriate, statements of the various stakeholders. Results: Various nomenclatures have been used to describe the concept of drug repurposing in the literature, with more or less broad definitions either based on outcomes, processes, or being a mix of both. In this context, Medicines for Europe (http://www.medicinesforeurope.com/value-added-medicines/) established one single terminology for these medicines, known as value added medicines, defined as ‘medicines based on known molecules that address healthcare needs and deliver relevant improvements for patients, healthcare professionals and/or payers’. Stakeholder interviews highlighted three main potential benefits for value added medicines: (1) to address a number of medicine-related healthcare inefficiencies related to irrational use of medicines, non-availability of appropriate treatment options, shortage of mature products, geographical inequity in medicine access; (2) to improve healthcare system efficiency; and (3) to contribute to sustainability of healthcare systems through economic advantages. Current HTA framework, generic stigma, and pricing rules, such as internal reference pricing or tendering processes in place in some countries, were reported as the current key hurdles preventing the full recognition of value added medicines’ benefits, discouraging manufacturers from bringing such products to the market. Discussion & conclusions: There is currently a gap between increasing regulatory authority interest in capturing value added medicines’ benefits and the resistance of HTA bodies/payers, who tend to ignore this important segment of the pharmaceutical field. This situation calls for policy changes to foster appropriate incentives to enhance value recognition of value added medicines and deliver the expected benefit to society. Policy changes from HTA perspective should include: absence of any legislative barriers preventing companies from pursuing HTA; HTA requirements proportionate to potential rewar...

On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients

“…The introduction of a new indication for a product that was already on the market can lead to price cuts because of a combination of price/volume agreements, external reference pricing, or budget impact analysis (Nayroles et al, 2017). In contrast, a company could ask for an increase in price to compensate for the investments made to develop the new indication, but payers are generally resistant to pay a higher price for a new indication of an existing medicinal product (Shineman et al, 2014; STAMP European Commission expert group, 2017a; Toumi and Rémuzat, 2017).…”

“…Alternatively, country-specific incentives may be offered, such as tax incentives [e.g., UK research and development (R&D) credits] or a differential pricing system across indications (Nayroles et al, 2017;Toumi and Rémuzat, 2017;Association of Medical Research Charities, 2017). Differential pricing systems would require the physician to report the indication on their prescriptions for patients, which can be facilitated with eprescribing software (Roin, 2013).…”

Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer

“…In a view of the continuous innovation development and technological progress in health systems, the issue of their financial sustainability becomes one of the most important points. Possibilities how to balance the quality, availability and efficiency of health care are sought [40]. The importance of addressing this issue has increased in relation to the demographic aging processes that take place in many regions nowadays [38].…”

За Стойността На Иновативните Терапии И Цената На Препрофилирането На Лекарствени Продукти

“…След икономическата криза от 2008 г. във всички европейски страни се наблюдава своеобразен натиск върху здравните бюджети. В областта на лекарствената политика навлязоха набор от мерки за насърчаване на рационалната употреба и ограничаване на разходите за лекарствени терапии [1]. Този подход е целесъобразен предвид необходимостта от повишаване на ефективността в здравеопазването и в частност при разпределянето на средствата.…”

“…Така могат да се осигурят нови терапевтични възможности при намалени време и разходи спрямо разработването на изцяло нови молекули. Неслучайно този подход е обект на интерес от страна на редица научноизследователски програми в САЩ и Европа [1,3].…”